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Introduction
Immunotherapy has become a major therapeutic strategy in oncology. The trail was blazed by ipilimumab, an antibody directed against Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), which demonstrated a significant survival benefit in patients with metastatic melanoma (MM) [1, 2] . It has previously been reported that 22% of MM patients treated with ipilimumab have prolonged survival [3] .
Ipilimumab reactivates T cells and therefore affects a much wider repertoire of T cells than those involved only in the anticancer response [4, 5] . This probably explains why blockade is associated with immune-related adverse events (irAE) [6, 7] . Colitis is the most frequent irAE associated with CTLA-4 blockade [7, 8] and severe colitis may need anti-TNF therapy and sometimes colectomy [8, 9] . In this context, reliable biomarkers of efficacy and/or toxicity ensuring the risk/benefit ratio optimization of this drug would be of paramount interest. Colitis due to ipilimumab shares several features with inflammatory bowel disease (IBD) [9] . In IBD, dysregulated inflammation is associated with a dysbiotic composition of the intestinal microbiota, which is proposed to be the antigenic driver of the disease [10] [11] [12] . In addition, studies carried out in mice have suggested that the microbiota composition is critical to promote an antitumor immune response to anti CTLA-4 and anti PDL-1 monoclonal antibodies [13, 14] .
Based on these data, we hypothesized that the ipilimumabinduced anti-cancer response, as well as immune-related enterocolitis associated with this agent, may depend on the gut microbiota. This prospective study was aimed to test this hypothesis in patients with MM treated with ipilimumab.
Patients, materials and methods

Data and materials availability
All data and materials are available from the corresponding author upon request. DNA sequence reads from this study have been submitted to the NCBI under the Bioproject ID PRJNA379764 and are available from the Sequence Read Archive (Biosamples accession numbers SAMN06620410 -SAMN06620492).
Patients
Patients with MM treated with ipilimumab were prospectively enrolled at the Gustave Roussy Cancer Campus between March 2013 and December 2014. Patients were informed of the study and consented to participate. This study was approved by the Kremlin Bicêtre Hospital Ethics Committee (GOLD study: SC12-018; ID-RCB-2012-A01496-37) and all procedures were carried out in accordance with the Declaration of Helsinki. Patients had a pre-specified clinical workup; feces and blood were collected at baseline (V 1 ), before each ipilimumab infusion (V 2 , V 3 , V 4 ), at the end of treatment (i.e. 3 weeks after the last infusion; V 5 ) and, if present, at the time of colitis occurrence (V Tox ). Ipilimumab was administered intravenously every 3 weeks at a dose of 3 or 10 mg/kg and could be continued after V 4 , at a maintenance dose of one infusion every 12 weeks, in patients whose disease was controlled (response or stable disease). When immune-mediated enterocolitis (!grade III) was suspected, patients were referred to the Gastroenterology Department of Bicêtre Hospital. The diagnosis of ipilimumab-induced colitis was made in patients who had endoscopic signs of inflammation and no other cause of colitis, such as ischemia and infection (stool tests for bacterial pathogens and Clostridium difficile toxin had to be negative).
Response to ipilimumab was assessed by several criteria. Long-term clinical benefit was defined by response decrease of tumor burden !50% relative to baseline, according to immune related response criteria [15, 16] or stable disease (decrease of tumor burden of less than 50% but with less than 25% increase relative to nadir) for more than 6 months. Patients with poor benefit were defined as patients with a lack of long-term benefit, i.e. with progression-free survival (PFS) of <6 months (with immune related progressive disease defined as a confirmed increase in tumor burden !25% relative to nadir) [15, 16] . All responses were confirmed by a subsequent assessment no less than 4 weeks from the date first documented. Use of antibiotics was also documented before each ipilimumab injection and is included in supplementary Table S3 , available at Annals of Oncology online.
Bacterial composition assessment by high-throughput sequencing
Fecal samples were collected anaerobically at baseline (V 1 ), before each ipilimumab infusion (V 2 , V 3 , V 4 ), at the end of the treatment (V 5 ) and at the time of colitis (V Tox ) and were kept at À80 C until analysis. Total DNA was extracted from fecal sample aliquots ($150 mg), as previously described using both physical and chemical lysis [17] . Cultureindependent 16S rRNA gene sequencing was carried out on 83 fecal samples (n ¼ 26 patients; supplementary Table S3 , available at Annals of Oncology online). Both 454 pyrosequencing (Life Sciences, a Roche company, Branford, CT) and MiSeq (Illumina, Inc., San Diego, CA) technologies were applied on the V 3 -V 4 16S rRNA gene region. Gut bacterial composition was determined prospectively without knowledge of colitis or of clinical benefit, which was determined at the end of the study. Details of bacterial composition assessment by high-throughput sequencing and statistical analyses can be found in supplementary materials, available at Annals of Oncology online.
Fresh whole blood immune monitoring and soluble immune markers
Blood samples were collected at baseline (V 1 ), before each ipilimumab infusion (V 2 , V 3 , V 4 ), at the end of treatment (V 5 ) and at the time of colitis (V Tox ). Phenotyping was carried out on fresh whole blood or on fresh peripheral blood mononuclear cells isolated by Ficoll density gradient and frozen for later analyses (see supplementary materials, available at Annals of Oncology online). All serum samples were stored at À80
C until further analysis of soluble immune markers of inflammation (IL-6, IL-8, IP-10, MCP-1, TNFa, sCD25) and bacterial translocation (sCD14). Details of immune monitoring can be found in supplementary materials, available at Annals of Oncology online. We monitored memory T cells and inducible Tcell COStimulator (ICOS) induction on T cells because previous studies had demonstrated that both could be related to clinical responses [18] . Regulatory T cells play a crucial role in the maintenance of immune homeostasis in the gut and are supposed to be a major target for anti-CTLA-4 treatment [19] . The heterodimer a4b7 plays a crucial role in the intestinal homing of T cells; we monitored a4
þ T cells to gain some insight in the mechanism of ipilimumab-induced colitis. We monitored soluble immune markers of inflammation and bacterial translocation as a complement to microbiota composition. Indeed, microbiota composition affects gut barrier function, local as well as systemic immunity [20] [21] [22] [23] [24] [25] 26] .
Statistical analyses
A formal sample-size calculation was not carried out for this pioneering study. Associations between microbiota dominant profile and immunological parameters were assessed with the Spearman correlation coefficient and a two-sided Wilcoxon test. No adjustment for multiple comparisons was made because of the exploratory component of the analyses. Fisher's exact test was used to examine the association between microbiota clusters and immune parameters; microbiota clusters and colitis, as well as microbiota clusters and clinical responses.
Overall survival (OS) and PFS according to intestinal microbiota (cluster A versus cluster B) and according to the number of conventional CD4 þ T cells (low number of conventional CD4 versus high number of conventional CD4) were estimated using the Kaplan-Meier method and compared using the log-rank test.
When considering the occurrence of toxicity, progression and death lead to informative censoring, because when patients are censored at progression or death, their risk of toxicity could differ from that of patients who are not censored. Competing risk analysis is a method to deal with competing events, in order to avoid selection bias induced by informative censoring.
Therefore, toxicity cumulative incidence function (CIF) was estimated through a competing risk analysis in which toxicity was the event of interest, death or progression was the competing event and patients alive without progression or toxicity at their last follow-up were censored from the date of last follow-up. The toxicity CIFs in the different gut microbiota clusters and for the different conventional CD4 levels were estimated using the SAS macro %CIF and compared using the stratified Gray's test [27, 28] . These analyses were carried out using SAS software, Version 9.4 (SAS Institute, Inc., Cary, NC).
Results
Clinical characteristics of the patients
Fifty-five patients were included in the study and followed-up for at least 6 months. Among them, 13 patients did not receive ipilimumab, while 4 patients received only a single infusion of ipilimumab and died soon thereafter due to their melanoma; they were therefore excluded from further analyses. Among the 38 remaining patients, 26 provided fecal samples at baseline (i.e. before the first dose of ipilimumab) for microbiota analysis. Nine of these 26 patients (34.6%) had a long-term clinical benefit and seven (26.9%) developed an immune-mediated colitis. The clinical characteristics of patients with or without colitis and with or without long-term clinical benefit are shown in supplementary Tables S1 and S2, available at Annals of Oncology online, respectively.
Microbiota composition is not modified by ipilimumab treatment, except at the time of colitis
The gut microbiota was not significantly modified over the course of the ipilimumab treatment. Main bacterial phyla, Firmicutes and Bacteroidetes, remained stable over time (supplementary Figure S1A , available at Annals of Oncology online). Even though bacterial genera proportions differed between the different time points, they were not significantly altered by ipilimumab treatment (Wilcoxon test P > 0.05; supplementary Figure S1B , available at Annals of Oncology online). Likewise, diversity was not altered by ipilimumab injections as assessed by both Shannon and Simpson indices (supplementary Figure S1C , available at Annals of Oncology online). Altogether these data indicate that ipilimumab does not induce a gut microbial dysbiosis in patients with MM.
Seven patients provided fecal samples both at baseline (V 1 ) and during colitis (V tox ). Immune-related colitis was associated with a shift in the gut microbial composition as highlighted on the principal component analysis (PCA; Figure 1A ). These differences were significant at the family level (Wilcoxon test, P ¼ 0.0049) and at the genus level (P ¼ 0.0059). The proportions of seven genera were significantly reduced by at least twofold at V tox, compared with V 1 ( Figure 1B) . They all belonged to the Firmicutes phylum (Ruminococcus, Lachnospiracea incertae sedis, Blautia, Clostridium IV, Eubacterium, unclassified Lachnospiraceae and Pseudoflavonifractor) and were dominant members of the microbiota. Similarly, 18 bacterial isolates, mostly Firmicutes, were significantly reduced between V 1 and V tox (paired Student's t-test P < 0.05, Figure 1C ). Finally, colitis was associated with a decreased bacterial diversity, as reflected by a lower Shannon diversity index at the time of colitis (V 1
Baseline microbiota composition is associated with subsequent clinical response and immune-related colitis
At V 1 , inter-class PCA based on genera composition showed a significant clustering of patients depending on their clinical benefit in response to ipilimumab, either long-term clinical benefit or poor clinical benefit (Monte-Carlo test, P ¼ 0.0090; Figure 2A ). This was also true at finer taxonomic levels such as species or OTUs composition (P ¼ 0.0050 and P ¼ 0.0080 respectively). Moreover, fecal microbiota at V 1 allowed the correct classification of 84.6% of patients into either the long-term or poor clinical benefit category, and the accuracy reached more than 99% (5000 bootstraps) for patients with poor benefit, as assessed by a Random Forest analysis. The receiver-operating characteristic curve provided an area under the curve (AUC) of 0.77, which indicates a fair classification based on overall microbial composition. Main genera accounting for this stratification are Faecalibacterium, Gemmiger, Bacteroides and Clostridium XIVa, and when proportions of these genera were solely considered for testing the stratification the classification power increased and the score was nearly excellent (AUC ¼ 0.895; supplementary Figure S2 , available at Annals of Oncology online). While high proportions of Bacteroides were present at baseline in patients with poor clinical benefit (Wilcoxon test, P ¼ 0.034), Faecalibacterium percentages were significantly higher in patients with long-term benefit (P ¼ 0.0092; Figure 2B ). Baseline fecal microbiota composition was also significantly associated with patients' OS and survival longer than 18 months (Wilcoxon test, P ¼ 0.011; Figure 2C ). All patients with an OS longer than 18 months could indeed be classified based on their gut microbial composition at V 1 and all showed higher proportions of OTUs affiliated to Firmicutes: Ruminococcus and Lachnospiraceae genus (relatives of Faecalibacterium prausnitzii L2-6, Gemmiger formicilis and butyrate-producing bacterium SS2-1; Figure 2D ). It should be noted that although prescription of antibiotics may alter microbiota composition, antibiotics before ipilimumab treatment does not influence baseline dominant microbiota and none of the potentially predictive OTUs or bacterial taxon were associated with antibiotic use (supplementary Figure S3 , available at Annals of Oncology online).
When the microbiota composition of patients was considered at baseline independently from their clinical characteristics and without a priori hypotheses (k-means clustering algorithm and CalinskiHarabasz index), three groups of patients emerged that were defined as clusters: clusters A, B and C. The inter-class PCA based on genera composition depending on belonging to any of these three clusters highlighted that this stratification was significant (Monte-Carlo test, P ¼ 0.00099; Figure 3A ). Microbiota of patients belonging to cluster A (n ¼ 12 at baseline) was driven by Faecalibacterium and other Firmicutes (unclassified Ruminococcaceae, Clostridium XIVa and Blautia). Cluster B (n ¼ 10 at baseline) was enriched in Bacteroides, and cluster C (n ¼ 4 at baseline) was enriched in Prevotella ( Figure  3B ). Clinical characteristics of patients according to microbiota clustering are described in supplementary Table S4 , available at Annals of Oncology online. Cluster A was associated with longer PFS than cluster B (P ¼ 0.0039; Figure 3D ) and, to a lesser extent, longer OS (P ¼ 0.051; Figure 3C ). Most of the 22 patients from the Bacteroides-driven cluster B (80%) received subsequent treatments, including anti-PD-1 agents in 50% of the patients while 58% of patients from the Faecalibacterium-driven cluster A were treated with subsequent therapies, but only 25% of them received anti-PD-1 agents. Cluster A was also associated with a higher proportion of long-term clinical benefit (8/12; 67%) compared with cluster B (0/ 10; P ¼ 0.0017, Fisher's exact test).
At the phyla level, microbiota of patients prone to develop colitis was enriched in Firmicutes at baseline (Wilcoxon test, P ¼ 0.009), while high proportions of Bacteroidetes was observed in patients who did not develop colitis (P ¼ 0.011; Figure 4A ). In competing risk analysis, belonging to cluster A (driven by Faecalibacterium and other Firmicutes) tended to be associated with a shorter colitis-free cumulative incidence compared with cluster B (driven by Bacteroides) (Gray's test; P ¼ 0.054, Figure  4B ). Using linear discriminant analysis effect size (LEfSe) analysis, 15 bacterial OTUs were detected as potential biomarkers either of colitis-free progression or colitis onset during ipilimumab treatment ( Figure 4C ). Five (out of six) OTUs from the Bacteroidetes phylum (such as B. uniformis, B. vulgatus and Parabacteroides distasonis) were associated with absence of colitis, whereas OTUs associated with subsequent colitis related mostly to the Firmicutes phylum (8/9 OTUs). Several of these potential colitis-predictive baseline OTUs (relatives of F. prausnitzii L2-6, butyrate producing bacterium L2-21 and G. formicilis ATCC 27749) were also associated with longer OS.
Baseline immune parameters related to microbiota clustering, clinical benefit and ipilimumab-induced colitis Twenty-six patients had both immune monitoring and microbiota composition analysis at V 1 . Patients from cluster C could not be included in this analysis due to the low number of patients belonging to this cluster (n ¼ 4). Since patients who belonged to cluster A (n ¼ 12) and cluster B (n ¼ 10) had no differences in GS0_6  GS0_6  GS6_9  GS6_9  GS6_9  GS6_9  GS6_9  GS9_12  GS9_12  GS9_12  GS9_12  GS12_18  GS12_18  GS12_18  GS12_18  GS12_18  GS12_18  GS12_18 GSs up18 GSs up18 GSs up18 GSs up18 GSs up18 GSs up18 GSs up18 GSs up18
Percentage of total reads (%) Boxplot of the percentages of four dominant (>1% of total reads) genera differentially represented between both groups, i.e. Bacteroides, Faecalibacterium, Clostridium XIVa and Gemmiger; LT_Benefit, long-term benefit versus Poor Benefit; *P <0.05; **P <0.001. (C) Inter-class principal component analysis representation of patient distribution based on bacterial genera composition at baseline (V 1 ) depending on overall survival time following ipilimumab treatment; GS0_6: overall survival ranging from 0 to 6 months (n¼2), GS6_9: overall survival ranging from 6 to 9 months (n¼5), GS9_12: overall survival ranging from 9 to 12 months (n¼4), GS12_18: overall survival ranging from 12 to 18 months (n¼7), GSsup18: overall survival superior to 18 months (n¼8). Monte-Carlo simulated P-value¼ 0.011. (D) Percentages of three specific OTUs highlighted as biomarkers at baseline (V 1 ) of overall survival duration >18 months. Each patient's microbiota are presented in the graph. GS0_6: overall survival ranging from 0 to 6 months (n¼2), GS6_9: overall survival ranging from 6 to 9 months (n¼5), GS9_12: overall survival ranging from 9 to 12 months (n¼4), GS12_18: overall survival ranging from 12 to 18 months (n¼7), GSsup18: overall survival >18 months (n¼8).
absolute counts of peripheral-blood CD4 þ and CD8 þ T cells (supplementary Table S5 , available at Annals of Oncology online), the main T cell subpopulations were considered as a percentage. Patients who belonged to the Faecalibacterium-driven cluster A had a low proportion of baseline regulatory T cells (Tregs), and had a significantly lower proportion of baseline a4
T cells, compared with those who belonged to the Bacteroides-driven cluster B ( Figure 5A ).
Patients with long-term benefit tended to have a lower frequency of regulatory T cells (P ¼ 0.056) and a lower frequency Figure  5B ). Although serum concentrations of several biomarkers of inflammation (IL-6, IL-8, IP-10, MCP-1, TNFa, sCD25) and sCD14 considered as a marker of bacterial invasion (translocation) were measured, none of these were associated with any cluster or clinical benefit at baseline (supplementary Tables S5  and S6 , available at Annals of Oncology online).
cells, compared with those with poor clinical benefit (
Patients who developed ipilimumab-induced colitis tended to have significantly higher absolute numbers of CD4þ T cells (P ¼ 0.053) and had significantly lower levels of IL-6, IL-8 and sCD25 at baseline compared with patients without colitis ( Figure 5C ; supplementary Table S7 , available at Annals of Oncology online). In competing risk analysis, patients with high numbers of conventional CD4 þ T cells had a shorter colitis-free cumulative incidence, compared with those with low numbers of conventional CD4 þ T cells (P ¼ 0.0038, supplementary Figure S4 , available at Annals of Oncology online). The median percentage of Tregs were lower before introduction of ipilimumab in patients who developed colitis during the course of ipilimumab compared with patients without colitis (2.5% versus 8.4%, P ¼ 0.018). However, absolute numbers of Tregs were not significantly different (supplementary Table  S7 , available at Annals of Oncology online). None of the other CD4 þ T cell subpopulations at baseline were related to colitis onset (supplementary Table S7 , available at Annals of Oncology online).
The ICOS molecule is significantly up-regulated on CD4 1 T cells after ipilimumab treatment in patients who belong to Faecalibacterium-driven cluster A Since immune parameters were monitored longitudinally, specific changes in immune activation during the course of ipilimumab treatment were assessed in patients from cluster A versus B. During ipilimumab treatment, ICOS was significantly increased on conventional CD4 þ T and Treg cells in patients who belonged to cluster A ( Figure 6A and B) , but not in those who belonged to cluster B (Figure 6A and B) . Given that ICOS is induced on CD4 þ T cells after IL-2 stimulation, concentration of sCD25, a marker of IL-2 impregnation [29, 30] , was surveyed during the course of ipilimumab treatment. Patients who belonged to cluster A showed a greater increase over time in sCD25 than patients from cluster B, as demonstrated by a higher V 2/3 to V 1 ratio compared with patients from cluster B ( Figure 6C ). 
Discussion
This study shows that a distinct baseline gut microbiota composition is associated with an anti-cancer response and immunemediated colitis in patients with MM treated with ipilimumab. Colonization by Firmicutes and more specifically by OTUs related to F. prausnitzii L2-6, butyrate producing bacterium L2-21 and G. formicilis ATCC 27749 is associated with both anti-cancer response and immune-related colitis. There is a higher representation of Bacteroidetes (mostly Bacteroides genus) in patients who have a poor anti-cancer response and who remain colitis-free. Dubin et al. recently showed an increased representation of bacteria belonging to the Bacteroidetes phylum among patients who remain free of ipilimumab-induced colitis in an American cohort of 34 patients [31] . Our results confirm these data in an independent cohort. Moreover, in our study, Bacteroides genus was also associated with poor response to anti-CTLA-4 treatment. Recent studies conducted in mice have shown that the efficacy of CTLA-4 and PDL-1 blockade is influenced by gut microbiota [13, 14] . In mice, anti-CTLA-4 treatment induced a microbial dysbiosis [13] that was not observed in our patients except at the time of ipilimumab-induced colitis. Furthermore, while we observed that higher proportions of Bacteroides at baseline were associated with minimal benefit of ipilimumab in patients, fecal microbiota transplantation (FMT) from patients with MM into mice recipients revealed that specific species from the Bacteroides genus (B. fragilis and/or B. thetaiotaomicron) could elicit the immunostimulatory effects of CTLA-4 blockade [13] . However, FMT of human feces in mice have several limitations due to a bias in the reconstitution of the microbiota and is more distant from the clinical setting than our study. In our study, we directly assessed the anti-cancer efficacy of ipilimumab in patients with MM. Finally, since specific bacterial groups were targeted by quantitative PCR in FMT experiments in mice, one cannot exclude that other species were involved in ipilimumab efficacy in this setting. In our dataset, B. fragilis and B. thetaiotaomicron were not abundantly represented at baseline (supplementary Figure S5 , available at Annals of Oncology online). Overall, these bacterial species were more abundant in patients with poor clinical benefit who remained colitis-free. We found that the Faecalibacterium-driven cluster A and clinical benefit were associated with low baseline percentage of circulating a4
þ T cells and CD4 þ Tregs. In addition, high proportions of F. prausnitzii, low baseline percentage of circulating CD4 þ Tregs and low baseline levels of systemic inflammatory proteins, such as IL-6, IL-8 and sCD25, were associated with subsequent colitis. Commensal bacteria, such as F. prausnitzii, and 
þ T and CD8 þ T cells, serum concentrations of IL-6, IL-8 and sCD25 were analyzed and compared between patients belonging to cluster A and patients belonging to cluster B (A); long-term clinical benefit (LT benefit) and poor clinical benefit (poor benefit) (B); patients with colitis (Colitis) and patients without colitis (No colitis) (C). Each dot represents one patient. P values are indicated on each graph; ns means "not significant"; Mann-Whitney tests were used.
several butyrate-producing bacteria promote the development of tolerogenic macrophages and dendritic cells, as well as induced and thymic Treg accumulation, and thereby contribute to the anti-inflammatory balance of the intestines [32, 33] . It has been suggested that F. prausnitzii have an anti-inflammatory role in IBD. Low abundance of F. prausnitzii and high amounts of Enterobacteriaceae predicted subsequent relapse in patients who had received an ileocaecal resection for Crohn's disease [23] . Although it is currently hypothesized that dysbiosis precedes IBD, until now it has not been possible to have access to pre- Figure 6 . Ipilimumab-induced blood immune modifications and baseline microbiota composition. The expression of ICOS on CD4 þ T cells was monitored in fresh whole blood before ipilimumab treatment (V 1 ) and after one or two injections of ipilimumab (V 2-3 ). Serum concentration of sCD25 was monitored before ipilimumab treatment (V 1 ) and after one or two injections of ipilimumab (V 2-3 ). Percentage of conventional CD4 þ T cells (Tconv) was defined as %CD3 þ CD4 þ T excluding Treg cells. Graphs depict specific changes in Treg cells (A), Tconv cells (B) and sCD25 (C) over the course of ipilimumab treatment in patients belonging to cluster A (white circles) and patients belonging to cluster B (black circles). For sCD25, V 2-3 to V 1 ratio was calculated [(sCD25 at V 2-3 )/(sCD25 at V 1 )] for patients from clusters A and B (C, right). Each dot represents one patient. P values are indicated on each graph. Wilcoxon matched-pairs signed rank (A, B and C, left) or Mann-Whitney (C, right) tests were used.
illness microbiota in patients with IBD. The anti-inflammatory role of F. prausnitzii is based upon studies carried out in CD siblings and patients who already have the disease, whereas we studied patients before they received ipilimumab. Future studies will determine whether there is a specific microbiota associated with the subsequent development of IBD, and if it is close or far from that of patients who will develop colitis during ipilimumab treatment. However, our microbiota and immune monitoring data seem consistent. Baseline serum concentrations of proinflammatory cytokines were low in patients who developed colitis and in those who belonged to cluster A-this is in line with the anti-inflammatory role of F. prausnitzii and other Firmicutes. Previous studies have described correlations between specific components of the gut microbiota and systemic proinflammatory cytokine levels [21] . In our study, higher systemic inflammatory proteins and high proportions of Bacteroidetes at baseline were associated with resistance to colitis. Bacteroides enrichment has been shown to be associated with low-grade systemic inflammation, as opposed to anti-inflammatory species, such as F. prausnitzii [22] [23] [24] 34] .Taken together, these data suggest that the concentration of systemic inflammatory proteins at baseline might reflect microbiota composition and predict colitis in patients treated with ipilimumab. High proportion and numbers of a4 þ b7 þ T cells before ipilimumab treatment was associated with cluster B and poor benefit in patients. A previous paper has studied microbiota composition and blood T cell phenotype in patients with Crohn's disease, their related siblings and healthy controls. It showed that patients and siblings had a lower fecal concentrations of Faecalibacterium prausnitzii and a higher percentage and numbers of circulating b7 þ T cells [35] , as we observed in patients from cluster B in our cohort. Ipilimumab blocks CTLA-4, a major peripheral tolerance mechanism. Regulatory T cells have a critical role in regulating the development of colitis and Treg cells express high levels of CTLA-4. It has been showed that F. prausnitzii is associated with an augmentation/induction of regulatory T cells in the gut. Thus, we can speculate that F. prausnitzii could be associated with a sequestration of a4 þ b7 þ T cells and Tregs within the intestines and, possibly, tumor beds. Treg cells harbor high levels of CTLA-4 and are therefore vulnerable to ipilimumab [36] . Consequently, ipilimumab could induce the inactivation of intratumoral and gutassociated CTLA-4 þ Treg cells leading to effector T cell activation and therefore anti-cancer response as well as colitis development.
In addition, patients who belong to the Faecalibacteriumdriven cluster A have a higher ICOS induction on CD4 þ T cells and a higher increase in sCD25 ( Figure 6 ). These results are reminiscent of previous studies where ICOS induction on CD4 þ T cells during the course of ipilimumab treatment has been proposed as a biomarker of ipilimumab efficacy in patients with cancer [18, 37, 38] . sCD25 is a biomarker that has been associated with IL-2 impregnation [30] and IL-2 is a major growth factor for T cells, particularly regulatory Treg cells which respond to IL-2 treatment even at low dosage. CTLA-4 engagement prevents ICOS expression [29] while IL-2 is a great inducer of ICOS expression on T cells, particularly on Treg cells that express constitutionally high affinity IL-2R chain (CD25 or IL-2Ra) [39] [40] [41] [42] . Taken together, these observations suggest that gut microbiota composition at baseline could predict which patients will adequately respond to ipilimumab.
It can be argued that colitis could have been a time-dependent confounder on the causal relationship between microbiota composition and clinical response. However, it could induce an opposite bias, with a decrease of the benefit in the patients with colitis in whom ipilimumab treatment is stopped prematurely. We conducted a sensitivity analysis in the subgroup of patients who remained colitis-free. At the OTU level, the PCA was statistically significant (P ¼ 0.048), and there was a trend at the genera level (Monte-Carlo P-value ¼ 0.084). The tendency for the 4 specific genera showed a similar trend, but differences were not significant anymore. While F. prausnitzii L2-6 was still significantly associated with patients having an OS longer than 18 months (P ¼ 0.031), significance was lower for G. formicilis (P ¼ 0.064) and for butyrate-producing bacterium SS2-1 (P ¼ 0.10) in this sub-cohort. In conclusion, trends between baseline microbiota composition and response to ipilimumab were similar in these small subgroups and in the whole group.
Our results suggest that baseline gut microbiota composition may be an important determinant of response and colitis associated with anti-CTLA-4 treatment. Further studies are needed to compare the predictive value of microbiota with that of other markers, and to explore these parameters in the context of various types of tumors and anticancer treatments. The combination of anti-CTLA-4 and anti-PD1 blockade was recently approved for the treatment of patients with MM and is also in development in other tumor types based on increased response rates (50%-60%) and prolonged PFS [43, 44] . The results in terms of OS will be available in the following months. However, this combination is much more toxic than each of the drugs given as monotherapy, with close to 60% grades 3-5 adverse events, many of them being severe colitis, and interruption of treatment in 40% of patients because of toxicity [43, 44] . One of the main objectives of several research teams in this field is thus to identify baseline parameters that could help to identify patients who need the combination versus those who could be controlled with a monotherapy and not expose them to the risk of developing severe adverse events. Microbiome prospective studies similar to our present study will therefore be critical to conduct in patients treated with anti-PD1 drugs alone or in combination with ipilimumab to identify potential favorable versus hostile flora in the context of these distinct immunotherapies. It will also be very important to conduct such studies in various tumor types to evaluate the impact of the microbiome in different tumors and with different drugs, since checkpoint inhibitors are now being investigated in a wide range of tumors.
